New pill targets Hard-to-Treat cancers with RAS mutations
NCT ID NCT06895031
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new oral drug called JYP0015 in people with advanced solid tumors (such as pancreatic, lung, or colorectal cancer) that have a RAS mutation. The drug aims to block the activity of the mutated RAS protein, which drives cancer growth. The trial will enroll 210 participants to evaluate safety, tolerability, and how well the drug shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JYP0015 (a pan-RAS inhibitor pill)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced cancers that have specific RAS mutations, potentially shrinking tumors or slowing disease progression.
- What could go wrong
- This is an early-phase trial (Phase I/II) with a small number of participants, so the drug may not work as hoped or could cause unexpected side effects. It is not yet proven to be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?